Davide Capodanno

We authored the editorial “Science Behind the Study” for
@NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of the Factor XI inhibitor abelacimab in patients with atrial fibrillation.

A clinical consensus statement from the EAPCI outlining procedural and technical requirements to enhance the efficacy and safety of PCI in patients with reduced ejection fraction deemed not suitable for CABG.
eurointervention.pcronline.com/article/high...

There is everything you might expect (e.g., bifurcations, chronic total occlusions, drug-coated balloons), but also something surprising (inflammation, robotics, artificial intelligence), in the 2024 ranking of the most trending papers on EuroIntervention.

With the expanded indications for TAVI, a growing number of patients may outlive their initial transcatheter heart valve. This review addresses key considerations for lifetime management of these patients.
eurointervention.pcronline.com/article/life...

Are all stents the same for high bleeding risk patients? We wrote a brief article on the topic.
www.tandfonline.com/doi/full/10....

When I saw the results of the TCW trial at EuroPCR, I thought the results were too good to be true. The NI margin seemed too wide, and I doubted we would see the paper published anytime soon, let alone in a high-impact journal. But here we are – it’s in The Lancet.
www.thelancet.com/journals/lan...

After SENIOR RITA, I still have doubts about treating older patients with acute coronary syndromes. Although the trial was formally neutral, those treated with an invasive strategy had fewer spontaneous re-infarctions. We just published this debate.
eurointervention.pcronline.com/article/elde...